Julie Person
Chief Administrative Officer at THIRD HARMONIC BIO, INC.
Net worth: - $ as of 30/05/2024
Profile
Julie Person is currently the Chief Administrative Officer at Third Harmonic Bio, Inc. She previously worked as the Vice President-Human Resources at Sangamo Therapeutics, Inc. from 2019 to 2020.
She also held the position of Head-Human Resources at Astellas Gene Therapies, Inc. Additionally, Julie served as the Chief People Officer at Neumora Therapeutics, Inc. from 2021 to 2022.
Prior to that, she was the VP-Talent Management & Organizational Development at Shire Plc from 2017 to 2019.
Ms. Person completed her undergraduate degree at St. Mary's College of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
THIRD HARMONIC BIO, INC.
-.--% | 03/04/2024 | 0 ( -.--% ) | - $ | 30/05/2024 |
Julie Person active positions
| Companies | Position | Start |
|---|---|---|
| THIRD HARMONIC BIO, INC. | Chief Administrative Officer | 31/05/2022 |
Former positions of Julie Person
| Companies | Position | End |
|---|---|---|
| NEUMORA THERAPEUTICS, INC. | Human Resources Officer | 31/05/2022 |
| SANGAMO THERAPEUTICS, INC. | Human Resources Officer | 31/03/2020 |
| SHIRE | Human Resources Officer | 28/02/2019 |
| AUDENTES THERAPEUTICS, INC. | Human Resources Officer | - |
Training of Julie Person
| St. Mary's College of California | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| NEUMORA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Julie Person
